Literature DB >> 16052457

The global HIV vaccine enterprise.

José Esparza1.   

Abstract

AIDS, which twenty-five years ago no one even knew it existed, has become the most serious infectious disease worldwide. The development of an HIV vaccine is one of the most difficult challenges that modern biomedical science is confronting. To address this challenge, scientists may need to organize themselves in a more intense, targeted, and collaborative effort, such as the one proposed by the Global HIV/AIDS Vaccine Enterprise. The enterprise concept proposes to complement the creativity of individual investigators with a collaborative system that ensures a more effective use of human and financial resources to produce new scientific knowledge. It also implies that the scientific knowledge can be harnessed in a targeted way to develop practical solutions to urgent global health problems, including explicit product development activities. Different modalities of the enterprise concept are being explored for the development of drugs to treat tuberculosis and vaccines to prevent malaria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052457

Source DB:  PubMed          Journal:  Int Microbiol        ISSN: 1139-6709            Impact factor:   2.479


  12 in total

1.  A gp41-based heteroduplex mobility assay provides rapid and accurate assessment of intrasubtype epidemiological linkage in HIV type 1 heterosexual transmission Pairs.

Authors:  Olivier Manigart; Debrah I Boeras; Etienne Karita; Paulina A Hawkins; Cheswa Vwalika; Nathan Makombe; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-03       Impact factor: 2.205

2.  Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.

Authors:  Derseree Archary; Rong Rong; Michelle L Gordon; Saikat Boliar; Maphuti Madiga; Elin S Gray; Anne-Sophie Dugast; Tandile Hermanus; Philip J R Goulder; Hoosen M Coovadia; Lise Werner; Lynn Morris; Galit Alter; Cynthia A Derdeyn; Thumbi Ndung'u
Journal:  Virology       Date:  2012-09-18       Impact factor: 3.616

3.  A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.

Authors:  Jue Hou; Shuhui Wang; Manxue Jia; Dan Li; Ying Liu; Zhengpeng Li; Hong Zhu; Huifang Xu; Meiping Sun; Li Lu; Zhinan Zhou; Hong Peng; Qichen Zhang; Shihong Fu; Guodong Liang; Lena Yao; Xuesong Yu; Lindsay N Carpp; Yunda Huang; Julie McElrath; Steve Self; Yiming Shao
Journal:  J Immunol       Date:  2017-07-07       Impact factor: 5.422

4.  Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines.

Authors:  Taheri Sathaliyawala; Mangala Rao; Danielle M Maclean; Deborah L Birx; Carl R Alving; Venigalla B Rao
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

5.  Restriction of HIV-1 genotypes in breast milk does not account for the population transmission genetic bottleneck that occurs following transmission.

Authors:  Laura Heath; Susan Conway; Laura Jones; Katherine Semrau; Kyle Nakamura; Jan Walter; W Don Decker; Jason Hong; Thomas Chen; Marintha Heil; Moses Sinkala; Chipepo Kankasa; Donald M Thea; Louise Kuhn; James I Mullins; Grace M Aldrovandi
Journal:  PLoS One       Date:  2010-04-20       Impact factor: 3.240

6.  Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates.

Authors:  Ashika Singh; Taryn Page; Penny L Moore; Rachel L Allgaier; Keshni Hiramen; Hoosen M Coovadia; Bruce D Walker; Lynn Morris; Thumbi Ndung'u
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

7.  Equivalence of ELISpot assays demonstrated between major HIV network laboratories.

Authors:  Dilbinder K Gill; Yunda Huang; Gail L Levine; Anna Sambor; Donald K Carter; Alicia Sato; Jakub Kopycinski; Peter Hayes; Bridget Hahn; Josephine Birungi; Tony Tarragona-Fiol; Hong Wan; Mark Randles; Andrew Raxworthy Cooper; Aloysius Ssemaganda; Lorna Clark; Pontiano Kaleebu; Steven G Self; Richard Koup; Blake Wood; M Juliana McElrath; Josephine H Cox; John Hural; Jill Gilmour
Journal:  PLoS One       Date:  2010-12-14       Impact factor: 3.240

Review 8.  An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.

Authors:  Marc H V Van Regenmortel
Journal:  Front Immunol       Date:  2014-11-18       Impact factor: 7.561

Review 9.  Molecular and chemical engineering of bacteriophages for potential medical applications.

Authors:  Katarzyna Hodyra; Krystyna Dąbrowska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-07-22       Impact factor: 4.291

10.  The discovery value of "Big Science".

Authors:  José Esparza; Tadataka Yamada
Journal:  J Exp Med       Date:  2007-04-09       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.